| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 1. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | sitagliptin (Januvia®) |
| Formulation | 100 mg film-coated tablet |
| Reference number | 474 |
| Indication | In combination with PPAR gamma agonist and metformin for the treatment of patients with type 2 diabetes mellitus to improve glycaemic control when diet and exercise plus dual therapy with PPAR gamma agonist and metformin does not provide adequate glycaemic control |
| Company | Merck Sharp & Dohme Ltd |
| BNF chapter | Endocrine system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 17/08/2009 |